EDAP TMS S.A., a medical technology firm headquartered in Lyon, France, since its inception in 1979, innovates, manufactures, and globally distributes advanced, minimally invasive medical devices. With a primary focus on addressing urological diseases through sophisticated solutions, the company operates across Asia, France, the United States, and other international markets. Its business operations are divided into three distinct segments: 1. High Intensity Focused Ultrasound (HIFU): This segment concentrates on developing and advancing HIFU technology for the minimally invasive treatment of urological and various other clinical indications. Its product portfolio encompasses the Ablatherm, an ultrasound-guided robotic HIFU device for organ-confined prostate cancer; the Ablatherm Fusion, which features proprietary fusion software that merges MRI and ultrasound images for precise targeting; and the Focal One, a robotic HIFU device specifically designed for the focal therapy of prostate cancer. The segment also provides necessary disposables, leasing and treatment-related services, and ongoing maintenance. 2. Extracorporeal ShockWave Lithotripsy (ESWL): This division is responsible for manufacturing and marketing lithotripters utilizing ESWL technology to treat urinary tract stones. Its flagship, the Sonolith i-move, is an extracorporeal shockwave lithotripter well-suited for small to mid-sized hospitals, with accompanying sales of disposable parts and electrodes. 3. Distribution Services (DIST): This segment oversees the marketing, distribution, and servicing of various medical products from third-party manufacturers, such as lasers and micro-ultrasound systems. This segment's offerings also extend to device leasing, the sale of disposables and spare parts, and comprehensive maintenance support. The company serves a broad customer base, including hospitals, urology clinics, and research institutions, leveraging both its direct marketing, sales, and service platform, as well as a network of third-party distributors and agents.